Skip to content
DataLookout
Menu

NCT05076617

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

StatusEnrolling by Invitation
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Sep 26, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

The 50 most recent of 90 versions: 41 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 136 → 133 locations
  2. Notable Eligibility criteria expanded, about 20 words
    • Study sites: 137 to 136
    • Secondary endpoints: details revised at 1 of 3 entries
  3. Minor Trial sites reduced: 140 → 137 locationsv89
  4. Minor Trial sites reduced: 146 → 140 locationsv88
  5. Minor Site details revised at 2 of 146 sitesv86
Show 37 earlier versionsHide 37 earlier versions
  1. Minor Study sites: 145 to 146v84
  2. Minor Study sites: 144 to 145v82
  3. Minor Study sites: 143 to 144v81
  4. Minor Study sites: 141 to 143v78
  5. Minor Study sites revised (141)v77
  6. Minor Site details revised at 2 of 141 sitesv76
  7. Minor Study sites: 139 to 141v75
  8. Minor Study sites: 140 to 139v74
  9. Study Status, Outcome Measures, Eligibilityv73
  10. Minor Study sites: 139 to 140v72
  11. Minor Study sites: 135 to 139v71
  12. Minor Study sites: 143 to 135v70
  13. Minor Study sites: 141 to 143v69
  14. Minor Study sites: 140 to 141v68
  15. Minor Study sites: 139 to 140v67
  16. Minor Study sites: 138 to 139v66
  17. Minor Study sites: 137 to 138v64
  18. Minor Study sites: 135 to 137v63
  19. Minor Study sites: 132 to 135v62
  20. Minor Study sites: 129 to 132v60
  21. Minor Study sites: 136 to 129v58
  22. Notable Primary and study completion dates: May 22, 2026 to Nov 30, 2028v57
  23. Minor Study sites: 135 to 136v56
  24. Minor Study sites: 134 to 135v54
  25. Minor Study sites: 133 to 134v53
  26. Minor Study sites: 137 to 133v52
  27. Minor Study sites: 136 to 137v51
  28. Minor Site details revised at 1 of 136 sitesv50
  29. Minor Site details revised at 1 of 136 sitesv49
  30. Minor Study sites: 138 to 136v48
  31. Minor Study sites: 139 to 138v47
  32. Minor Study sites: 138 to 139v46
  33. Minor Study sites: 137 to 138v45
  34. Minor Study sites: 139 to 137v44
  35. Minor Study sites: 138 to 139v43
  36. Minor Study sites: 137 to 138v42
  37. Minor Study sites: 135 to 137v41
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Frequency of treatment-emergent adverse events (TEAEs)
Timeframe: From Baseline up to the End of Study Visit (up to 78 months)
Frequency of TEAEs leading to withdrawal from study
Timeframe: From Baseline up to the End of Study Visit (up to 78 months)
Frequency of serious TEAEs
Timeframe: From Baseline up to the End of Study Visit (up to 78 months)

Secondary (3)

Treatment success after investigational medicinal product (IMP) administration for seizures occurring within the first 12 months
Treatment success after IMP administration with no recurrence after 2 hours for seizures during the first 12 months
Frequency of respiratory TEAEs

Arms and interventions

Staccato alprazolamExperimental

Participants will receive Staccato alprazolam by inhalation.

Drugs: Staccato alprazolam

Sites

133 sites in 12 countries

United States 45, China 25, Japan 18, Spain 8, Poland 6, Czechia 5, Germany 5, Italy 5, United Kingdom 5, Bulgaria 4, Hungary 4, Australia 3